American Philosophical Society
Member History

Results:  48 ItemsModify Search | New Search
Page: Prev  1 2 3  NextReset Page
Residency
International (13)
Resident (34)
Class
Subdivision
204. Medicine, Surgery, Pathology and Immunology[X]
21Name:  Dr. Harald zur Hausen
 Institution:  German Cancer Research Center (Deutsches Krebsforschungszentrum)
 Year Elected:  1998
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  International
 Living? :   Deceased
 Birth Date:  1936
 Death Date:  May 28, 2023
   
 
Harald zur Hausen is a world renowned virologist who has made pioneering discoveries on viruses that cause human tumors. He made major contributions to our knowledge of the Epstein-Barr virus, the agent involved in Burkitt's lymphoma and nasopharyngeal carcinoma. His most important discovery, for which he was awarded the 2008 Nobel Prize in Medicine, is the causative role of papillomaviruses in human anogenital cancer. His work has far-reaching implications for human health and well-being and provides the basis for antiviral vaccines that could prevent some of the most common human malignancies. As Director of the German Cancer Research Center since 1983, Dr. zur Hausen has had a major influence on the organization, development and support of science. He has turned this institution into a leading center for biological and clinical research. A graduate of the University of Dusseldorf (M.D., 1960), Dr. zur Hausen is a member of the European Molecular Biology Organization (1976); the Heidelberg Academy of Sciences (1986); the German Academy of Natural Sciences (1986); the Academia Europaea (1990); the Polish Academy of Sciences (foreign member) (1991); and the Venezuelan National Academy of Medicine (1993).
 
22Name:  Dr. Michael Heidelberger
 Institution:  New York University
 Year Elected:  1968
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Deceased
 Birth Date:  1888
 Death Date:  6/25/91
   
23Name:  Sir Harold Himsworth
 Institution:  Medical Research Council
 Year Elected:  1972
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  International
 Living? :   Deceased
 Birth Date:  1905
 Death Date:  11/1/93
   
24Name:  Dr. Charles B. Huggins
 Institution:  University of Chicago
 Year Elected:  1962
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Deceased
 Birth Date:  1901
 Death Date:  1/12/97
   
25Name:  Dr. Niels Kaj Jerne
 Institution:  Basel Institute for Immunology
 Year Elected:  1979
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  International
 Living? :   Deceased
 Birth Date:  1911
 Death Date:  10/7/94
   
26Name:  Dr. William G. Kaelin
 Institution:  Dana-Farber Cancer Institute and Harvard Medical School; Howard Hughes Medical Institute
 Year Elected:  2024
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Living
 Birth Date:  1957
   
 
William Kaelin is the Sidney Farber Professor of Medicine at Harvard Medical School and Dana- Farber Cancer Institute, Senior Physician-Scientist at Brigham and Women's Hospital and Howard Hughes Medical Institute Investigator. He obtained his undergraduate and M.D. degrees from Duke University and completed his training in Internal Medicine at the Johns Hopkins Hospital, where he served as chief medical resident. He was a clinical fellow in Medical Oncology at the Dana-Farber Cancer Institute and later a postdoctoral fellow in David Livingston’s laboratory, during which time he was a McDonnell Scholar. A Nobel Laureate, Dr. Kaelin received the 2019 Nobel Prize in Physiology or Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the National Academy of Medicine, the American Society of Clinical Investigation, and the American College of Physicians. He previously served on the National Cancer Institute Board of Scientific Advisors, the AACR Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan- Kettering Cancer Center; the Richard and Hinda Rosenthal Prize from the AACR; the Doris Duke Distinguished Clinical Scientist award; the 2010 Canada International Gairdner Award; ASCI’s Stanley J. Korsmeyer Award; the Scientific Grand Prix of the Foundation Lefoulon-Delalande; the Wiley Prize in Biomedical Sciences; the Steven C. Beering Award; the AACR Princess Takamatsu Award; the ASCO Science of Oncology Award; the Helis Award; the Albert Lasker Basic Medical Research Prize; the Massry Prize; the Harriet P. Dustan Award for Science as Related to Medicine from the American College of Physicians. Dr. Kaelin’s research seeks to understand how, mechanistically, mutations affecting tumor- suppressor genes cause cancer. His laboratory is currently focused on studies of the VHL, RB-1, and p53 tumor suppressor genes. His long-term goal is to lay the foundation for new anticancer therapies based on the biochemical functions of such proteins. His work on the VHL protein helped to motivate the eventual successful clinical testing of VEGF inhibitors for the treatment of kidney cancer. Moreover, this line of investigation led to new insights into how cells sense and respond to changes in oxygen, and thus has implications for diseases beyond cancer, such as anemia, myocardial infarction, and stroke. His group also showed that leukemic transformation by mutant IDH was reversible, setting the stage for the development and approval of mutant IDH inhibitors, and discovered how thalidomide-like drugs kill myeloma cells by degrading two otherwise undruggable transcription factors.
 
27Name:  Dr. Yuet Wai Kan
 Institution:  University of California, San Francisco
 Year Elected:  2009
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Living
 Birth Date:  1936
   
 
Yuet Wai Kan is a graduate of the University of Hong Kong Medical School and is at present the Louis K. Diamond Professor of Hematology at the University of California, San Francisco. He has served on many organizations including as the President of the American Society of Hematology (1990) and currently as Chairman of the Croucher Foundation in Hong Kong that supports science and technology in Hong Kong. He works in the fields of hematology and genetics, and his research led to the innovation of DNA diagnosis that has found wide applications in many human conditions. In recognition of his contributions, he has been elected a member of learned science academies in the United States, Great Britain, Taiwan and China. He has received several honorary degrees and many national awards, including the Lasker Award for Medical Research (1991), international awards from Canada, Italy and Switzerland, and most recently the Shaw Prize in Life Sciences and Medicine from Hong Kong (2004). He was elected a member of the Institute of Medicine in 2011.
 
28Name:  Dr. Ho-Wang Lee
 Institution:  National Academy of Sciences, Republic of Korea
 Year Elected:  1998
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  International
 Living? :   Deceased
 Birth Date:  1928
 Death Date:  July 5, 2022
   
 
As a medical virologist, Ho-Wang Lee studied Japanese encephalitis (JE) and Korean hemorrhagic fever (KHF), now called Hemorrhagic fever with renal syndrome (HFRS). The first of these was the success of tissue culture of JE virus, immune mechanism of JE and overwintering mechanisms of JE virus in Korea from 1955-68. The second of these was the isolation of etiologic agents, epidemiology and prevention of HFRS from 1969-o 2004. He isolated etiologic agents of HFRS from Apodemus mice and urban rats and named the virus Hantaan and Seoul in 1976 and 1980, respectively. He elucidated epizootiology and epidemiology of HFRS in 1979-85. Hantaan virus is the origin of genus Hantavirus and he proved world-wide distribution of hantaviruses from 1977-2000. In 1990, he and his colleagues developed a simple rapid diagnostic kit and an inactivated vaccine against HFRS. This vaccine was distributed in Asia and thereafter the number of HFRS patients decreased significantly.
 
29Name:  Dr. John Nichols Loeb
 Institution:  Columbia University
 Year Elected:  1998
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Living
 Birth Date:  1935
   
 
John N. Loeb is Professor Emeritus of Medicine and Special Lecturer in Medicine at Columbia University. He graduated summa cum laude from both Harvard College and Harvard Medical School and after a year of internship at the Massachusetts General Hospital moved to New York City in 1962 for a year as an assistant resident on the Medical Service of the Presbyterian Hospital. After two years as a Research Associate with Gordon M. Tomkins in the Laboratory of Molecular Biology at the Institute of Arthritis and Metabolic Diseases at the National Institutes of Health, he returned to New York as Chief Resident in Medicine at the Presbyterian Hospital and Instructor in Medicine at the College of Physicians & Surgeons of Columbia University. He has remained affiliated with both institutions, where since 2005 he has been Professor Emeritus of Medicine and Special Lecturer in Medicine at Columbia University and continues as an Attending Physician at NewYork-Presbyterian Hospital. Dr. Loeb's research was principally focused on mechanisms of hormone action, the physical chemistry of receptor-ligand interactions and their quantitative relationship to biological response, and the regulation of glucose and monovalent cation transport. In pursuing these studies he chose to maintain only a small laboratory so that he could devote substantial time himself to benchwork, and his work was continuously funded by the National Institutes of Health from 1967 to 1999, support for the final ten years coming from an NIH MERIT award. From 1997 until 2003 he served as Associate Chairman for Research in the Department of Medicine and, from 2003 until his retirement, as Vice Chairman for Academic Affairs. Throughout his career Dr. Loeb has had an abiding interest in teaching both medical students and house staff, and in particular in bedside teaching. He has received numerous awards as a teacher at Columbia and additionally has devoted substantial time to teaching abroad. He received a Distinguished Service Award from the College of Physicians and Surgeons in 2007. Major non-scientific interests include nineteenth-century English and French literature and playing chamber music. Dr. Loeb was elected a member of the American Philosophical Society in 1998.
 
30Name:  Dr. Paul A. Marks
 Institution:  Memorial Sloan-Kettering Cancer Center
 Year Elected:  2007
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Deceased
 Birth Date:  1926
 Death Date:  April 28, 2020
   
 
Paul A. Marks was President Emeritus of Memorial Sloan-Kettering Cancer Center (MSKCC) and a member of the Sloan-Kettering Institute for Cancer Research. He was president and CEO of MSKCC from 1980-99. He received his A.B. and M.D. degrees from Columbia University and completed postdoctoral training at the National Institutes of Health, Bethesda, Maryland and the Pasteur Institute, Paris. Following his period at the Pasteur, Dr. Marks returned to Columbia College of Physicians and Surgeons as an assistant professor and was promoted to professor of medicine in 1967. In 1968 he was made professor of human genetics and Frode Jensen Professor of Medicine (1968-80) and the first chairman of the newly created Department of Human Genetics and Development. In 1970 he was elected Dean of the Faculty of Medicine (1970-73). In 1973 he became vice president of health sciences and director of the Comprehensive Cancer Center (1973-80) at Columbia University. In 1980 he was recruited to be the first president and CEO of the combined Memorial Hospital and Sloan-Kettering Institute. He retired from these positions in December 1999. Since January 2000 he has been a member of the Sloan-Kettering Institute, pursuing his research as head of the Laboratory of Cancer Cell Biology. Dr. Marks published over 400 scientific articles in various scholarly journals. His research focused on the discovery and development of approaches to selectively arrest cancer cell growth. He and his colleagues identified a series of small molecules - hydroxamic acid based hybrid polar compounds - that inhibit histone deacetylases (HDAC), enzymes that play a role in regulating gene expression, cell growth, and cell death and can cause death of a variety of cancer cells, with little or no toxicity to normal cells. SAHA was approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma (CTCL) in October 2006. The first of these novel targeted histone deacetylase inhibitors to be approved for patient use. HDAC inhibitors represent a new approach to cancer therapy. Dr. Marks was a member of the National Academy of Sciences and the Institute of Medicine and a fellow of the American Academy of Arts & Sciences. He served on many governmental and non-governmental committees and boards, including the President's Commission on Three Mile Island, the President's National Cancer Advisory Board, Councils of the National Academies and the boards of several academic institutions in the USA and abroad. He received a number of honors including the Distinguished Achievement Medal of Columbia University; the Japan Foundation for the Promotion of Cancer Research Medal; the Centenary Medal of the Pasteur Institute; honorary degrees from several universities, including his alma mater, Columbia University, the John Stearns Award for Lifetime Achievement in Medicine of the New York Academy of Medicine; and the President's National Medal of Science (USA). Dr. Marks was a founder of the biotechnology company Aton Pharma, Inc. that had an exclusive license from Columbia to develop SAHA as a cancer therapeutic, which is now a wholly owned subsidiary of Merck. Paul A. Marks was elected a member of the American Philosophical Society in 2007. He died April 28, 2020 in New York, New York, at the age of 93.
 
31Name:  Dr. Francis D. Moore
 Institution:  Harvard Medical School & Brigham & Women's Hospital
 Year Elected:  1998
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Deceased
 Birth Date:  1913
 Death Date:  November 24, 2001
   
32Name:  Sir Peter Morris
 Institution:  The Royal College of Surgeons of England; University of Oxford
 Year Elected:  2002
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  International
 Living? :   Deceased
 Birth Date:  1934
 Death Date:  October 29, 2022
   
 
Sir Peter Morris supplemented his medical education in Melbourne, Australia, with training at Guy's Hospital in London and the Massachusetts General Hospital. He returned to the University of Melbourne and obtained a Ph.D. in immunology in 1972. From 1974-2001, he was the Nuffield Professor of Surgery, chairman of the Department of Surgery, and director of the Oxford Transplant Centre at the University of Oxford. In 2001 he became President of the Royal College of Surgeons of England and chairman of the Council of the Institute of Health Sciences at the University of Oxford. He is also currently chairman of the British Heart Foundation and Director of the Centre for Evidence in Transplantation at the Royal College of Surgeons. His more than 700 papers deal with the entire field of clinical and experimental transplantation and immunology. He has contributed especially to the study of mechanisms of rejection, tolerance induction and pancreatic islet transplantation. He is one of the distinguished surgeon scientists of our time. In addition to his work in transplantation, in the earlier part of his career he made many contributions to knowledge of the association between HLA and disease, as well as playing a major part in the early anthropological studies of HLA around the Pacific rim. He is the editor of Kidney Transplantation: Principles and Practice, which is now in its 5th edition, and the widely acclaimed Oxford Textbook of Surgery, which is in its 2nd edition. Sir Peter Morris has received many honors, including the Medawar Medal, the Lister Medal and the Hunterian Medal. In 1996 he received knighthood from the Queen for services to medicine, and in 2004 he was made a Companion of the Order of Australia. He is a fellow of the Royal Society and a foreign member of the Institute of Medicine of the National Academy of Sciences. He served as president of the International Transplantation Society, the British Transplantation Society, the European Surgical Association and the International Surgical Society. He was elected a member of the American Philosophical Society in 2002.
 
33Name:  Dr. David G. Nathan
 Institution:  Dana-Farber Cancer Institute & Harvard Medical School
 Year Elected:  1999
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Living
 Birth Date:  1929
   
 
David Nathan is one of the most distinguished pediatric hematologists in the country. He has spent his career at Harvard University, where he has been a professor of medicine and professor of pediatrics, and in 1985 he was appointed Pediatrician-in-Chief at Childrens Hospital in Boston. In 1995 he became President of the Dana-Farber Cancer Institute. Dr. Nathan has brought to his position scientific excellence, great integrity and a warm humanity. Among other awards he has received the National Medal of Science (1990) and the Henry Stratton Medal of the American Society of Hematology (1995). He earned his M.D. from Harvard Medical School in 1955.
 
34Name:  Dr. Peter Carey Nowell
 Institution:  University of Pennsylvania
 Year Elected:  1993
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Deceased
 Birth Date:  1928
 Death Date:  December 26, 2016
   
 
A professor of pathology at the University of Pennsylvania from 1964 to his retirement in 2008, Peter Carey Nowell was a creative and distinguished scholar who was internationally recognized for discovery of the Philadelphia chromosome in granulocytic leukemia - the first constant chromosomal abnormality specifically associated with any form of cancer. This discovery led to the founding of an entirely new field of research: cancer cytogenetics. Some of Dr. Nowell's other important medical discoveries are less well known. He was the first to demonstrate that bone marrow transplantation could save lethally irradiated animals, and he was also the first to show that certain sugar-containing plant products (lectins) caused white blood cells to divide, a property that has been widely used in medical research. He also proposed a widely-accepted theory to explain the evolution of malignancy among the cells of tumors. With hundreds of publications to his credit, including more than a few "citation classics," Dr. Nowell was an academic leader who has served as both director of the cancer center and chairman of pathology at the University of Pennsylvania. In 1952 he received his M.D. from the University of Pennsylvania School of Medicine, and he has worked there throughout his career. A past president of the American Society for Experimental Pathology, Dr. Nowell was also a member of the National Academy of Sciences and the recipient of awards such as the Leukemia Society of America's Robert de Villiers Award (1987), the Memorial Sloan Kettering Cancer Center's Fred W. Stewart Award (1989), and the Franklin Institute's Benjamin Franklin Medal in Life Science (2009). Peter Nowell died December 26, 2016, at age 88.
 
35Name:  Dr. Paul A. Offit
 Institution:  Childrens Hospital of Philadelphia; University of Pennsylvania
 Year Elected:  2023
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Living
 Birth Date:  1951
   
 
Paul A. Offit, MD is the Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia as well as the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, and a Research Career Development Award from the National Institutes of Health. Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC in 2006 and by the WHO in 2013; for this achievement Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases; and was honored by Bill and Melinda Gates during the launch of their Foundation’s Living Proof Project for global health. In 2009, Dr. Offit received the President’s Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, Dr. Offit received the David E. Rogers Award from the American Association of Medical Colleges, the Odyssey Award from the Center for Medicine in the Public Interest and was elected to the Institute of Medicine of the National Academy of Sciences. In 2012, Dr. Offit received the Distinguished Medical Achievement Award from the College of Physicians of Philadelphia. In 2013, Dr. Offit received the Maxwell Finland award for Outstanding Scientific Achievement from the National Foundation for Infectious Diseases and the Distinguished Alumnus award from the University of Maryland School of Medicine. In 2015, Dr. Offit won the Lindback Award for Distinguished Teaching from the University of Pennsylvania and was elected to the American Academy of Arts and Sciences. In 2016, Dr. Offit won the Franklin Founder Award from the city of Philadelphia, The Porter Prize from the University of Pittsburgh School of Public Health, the Lifetime Achievement Award from the Philadelphia Business Journal, and the Jonathan E. Rhoads Medal for Distinguished Service to Medicine from the American Philosophical Society. In 2018, Dr. Offit received the Gold Medal from the Sabin Vaccine Institute and in 2019 the John P. McGovern Award from the American Medical Writers Association and in 2020 the Public Educator Award from CHILD USA. In 2021, Dr. Offit was awarded the Edward Jenner Lifetime Achievement Award in Vaccinology from the 15th Vaccine Congress and was elected to the Baltimore Jewish Hall of Fame. In 2022, Dr. Offit received the Mentor of the Year Award from the Eastern Society for Pediatric Research and the Dean’s Alumni Leadership Award from the University of Maryland School of Medicine. Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, is currently a member of the FDA’s Vaccine Advisory Committee and is a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research. He is also the author of ten medical narratives: The Cutter Incident: How America’s First Polio Vaccine Led to Today’s Growing Vaccine Crisis (Yale University Press, 2005), Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases (HarperCollins, 2007), for which he won an award from the American Medical Writers Association, Autism’s False Prophets: Bad Science, Risky Medicine, and the Search for a Cure (Columbia University Press, 2008), Deadly Choices: How the Anti-Vaccine Movement Threatens Us All (Basic Books, 2011), which was selected by Kirkus Reviews and Booklist as one of the best non-fiction books of the year, Do You Believe in Magic?: The Sense and Nonsense of Alternative Medicine (HarperCollins, 2013), which won the Robert P. Balles Prize in Critical Thinking from the Center for Skeptical Inquiry and was selected by National Public Radio as one of the best books of 2013, Bad Faith: When Religious Belief Undermines Modern Medicine (Basic Books, 2015), which was selected by the New York Times Book Review as an "Editor’s Choice" book in April 2015, Pandora’s Lab: Seven Stories of Science Gone Wrong (National Geographic Press/Random House, April 2017), which was nominated for Best Science and Technology book of 2017 by Goodreads, Bad Advice: Or Why Celebrities, Politicians, and Activists Aren’t Your Best Source of Health Information (Columbia University Press, June 2018), Overkill: When Modern Medicine Goes Too Far (HarperCollins, April, 2020), You Bet Your Life: From Blood Transfusions to Mass Vaccinations: The Long and Risky History of Medical Innovations (Basic Books, 2021), which was nominated for the Phi Beta Kappa Award in Science, and Tell Me When It’s Over: Living with COVID in a Post-Pandemic World (National Geographic Press, in press, 2024).
 
36Name:  Dr. Olufunmilayo Olopade
 Institution:  University of Chicago
 Year Elected:  2011
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Living
 Birth Date:  1957
   
 
Olufunmilayo Olopade occupies a unique place in medicine. Born and educated in Nigeria, where she earned her M.D. from the University of Ibadan in 1980, she has been on the faculty of University of Chicago since 1986. She specializes in cancer risk assessment prevention, early detection and treatment of aggressive breast cancer that disproportionately affects young women. Olopade has done pioneering work in genomic analysis of breast cancer, including seminal work in young Nigerian breast cancer patients harboring BRCA1 and BRCA2 variants. This work in comparative genomics has the potential to reduce the burden of cancer and improve health in developing nations. She has been recognized with many honors, including the Distinguished Clinical Scientist Award of the Doris Duke Charitable Foundation in 2000, a MacArthur Fellowship in 2005, and the 2017 Mendel Medal Lecture at Villanova University. She is a member of a number of scholarly communities, including the American Association for Cancer Research, the Association of American Physicians (2005), the National Academy of Sciences (2008), the Institute of Medicine (2008), and the American Academy of Arts & Sciences (2010). She was elected a member of the American Philosophical Society in 2011.
 
37Name:  Dr. Stuart H. Orkin
 Institution:  Harvard University; Howard Hughes Medical Institute
 Year Elected:  2017
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Living
 Birth Date:  1946
   
 
Stuart Orkin has made pioneering achievements in defining the molecular basis of blood disorders and fundamental regulatory mechanisms governing the development of blood stem cells and blood lineages. His research is unmatched for its combined impact on our understanding of the genetic basis of blood diseases, the control of hematopoiesis, and the basis of the human fetal (HbF) to adult hemoglobin switch. He provided the first comprehensive molecular dissection of an inherited disorder, the thalassemia syndromes, and isolated the first regulator of blood cell development (GATA1). He identified the first disease gene (X-linked chronic granulomatous disease) through positional cloning. In the past decade, he defined how HbF is silenced in adult red cells starting with genome-wide association studies (GWAS) through to gene editing, work that forms the basis for therapeutic trials to reactivate HbF in thalassemia and sickle cell disease patients. His research is a paradigm for the application of molecular genetics to medicine. In 2018 he was the recipient of the Mecthild Esser Nemmers Prize in Medical Science, in 2020 he was awarded the King Faisal Prize in Medicine, and in 2021 he was awarded the 2021 Gruber Genetics Prize.
 
38Name:  Sir Keith Peters
 Institution:  University of Cambridge & Christ's College
 Year Elected:  1999
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  International
 Living? :   Living
 Birth Date:  1938
   
 
Sir Keith Peters received his M.B. B.Ch. in Wales. He was a MRC clinical research fellow at the University of Birmingham and National Institute for Medical Research, London. He served as a lecturer in medicine at the Welsh National School of Medicine, honorary senior registrar in medicine at United Cardiff Hospitals, and professor of medicine and director of the department of medicine at the Royal Postgraduate Medical School. He is currently the Regius Professor of Physics and Head of the Clinical School at the University of Cambridge and a Fellow of Christ's College. He was honored as Knight Bachelor in 1993 and FRS in 1995. He is a member of the Academia Europaea, Association of Physicians, Association of American Physicians, British Society for Immunology, European Society of Clinical Investigation, Scandinavian Society for Immunology, and a foreign member of the National Academy of Sciences. Sir Keith Peters is the preeminent physician-scientist in the UK. His principle scientific contributions relate to kidney disease and, in particular, the immunopathology and therapy for nephritis. He utilized the technique of plasmaphoresis and demonstrated its usefulness in the arrest of certain immunologically related diseases. His scientific contributions to medicine earned him election to the Royal Society, an unusual honor for one who is predominately a clinical scientist. This honor represents only one aspect of Sir Keith's contribution to medicine and science. He has trained many of the current leaders in UK academic medicine and has transformed the Cambridge Medical Schools, not only by the erection of new buildings but by elegant and successful recruitment to Cambridge of scientifically committed physicians. The intellectual merger of medicine in Cambridge with the existing strengths in the biological sciences has now positioned Cambridge as the leading academic medical center in Europe. That he serves on the Gairdner Foundation Award Committee and the General Motors Cancer Research Foundation reflects the high opinion that Sir Keith enjoys in this country as well. He was elected as a member of the American Philosophical Society in 1999.
 
39Name:  Dr. Jonathan E. Rhoads
 Institution:  University of Pennsylvania
 Year Elected:  1958
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Deceased
 Birth Date:  1907
 Death Date:  January 3, 2002
   
40Name:  Dr. Frederick C. Robbins
 Institution:  Case Western Reserve University
 Year Elected:  1972
 Class:  2. Biological Sciences
 Subdivision:  204. Medicine, Surgery, Pathology and Immunology
 Residency:  Resident
 Living? :   Deceased
 Birth Date:  1916
 Death Date:  August 4, 2003
   
Election Year
2024 (2)
2023 (2)
2020 (1)
2017 (1)
2016 (1)
2011 (1)
2010 (1)
2009 (1)
2007 (1)
2005 (1)
2004 (1)
2002 (1)
2001 (2)
2000 (2)
1999 (4)
1998 (4)
1997 (1)
1995 (2)
1993 (1)
1989 (1)
Page: Prev  1 2 3  Next